^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    IDH1 mutation + BRAF V600E

    i
    Other names: HEL-216, HEL-S-26, Epididymis Luminal Protein 216, Isocitrate Dehydrogenase 1 (NADP+), Epididymis Secretory Protein Li 26, IDH1, Isocitrate Dehydrogenase (NADP(+)) 1, Isocitrate Dehydrogenase 1 (NADP+), Soluble, BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
    Entrez ID:
    673; 3417
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    8ms
    A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma (clinicaltrials.gov)
    P3, N=300, Recruiting, National Cancer Institute (NCI) | Suspended --> Recruiting
    Enrollment open • Combination therapy
    |
    BRAF (B-raf proto-oncogene) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NF1 (Neurofibromin 1)
    |
    BRAF V600E • BRAF V600 • IDH1 mutation • IDH1 mutation + BRAF V600E
    |
    Koselugo (selumetinib) • vinblastine
    1year
    A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma (clinicaltrials.gov)
    P3, N=300, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension • Combination therapy
    |
    BRAF (B-raf proto-oncogene) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NF1 (Neurofibromin 1)
    |
    BRAF V600E • BRAF V600 • IDH1 mutation • IDH1 mutation + BRAF V600E
    |
    Koselugo (selumetinib) • vinblastine
    over1year
    Systemic Therapy for Intrahepatic Cholangiocarcinoma: Current and Future Perspectives (APPLE 2023)
    BTC has immunogenic features. Immune checkpoint inhibitors
    BRCA Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA1 (Breast cancer 1, early onset) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • CCND1 (Cyclin D1) • BAP1 (BRCA1 Associated Protein 1) • SMAD4 (SMAD family member 4) • BRCA (Breast cancer early onset) • CCND3 (Cyclin D3)
    |
    BRAF V600E • BRAF V600 • IDH1 mutation • FGFR mutation • FGFR fusion • IDH1 mutation + BRAF V600E
    almost2years
    Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma. (PubMed, J Hepatol)
    Majority of patients are diagnosed with advanced disease, when chemotherapy with cisplatin and gemcitabine followed by second-line FOLFOX is the cornerstone of treatment in the absence of targetable alterations...We are therefore facing a change of paradigm, where immunotherapy, cytotoxic chemotherapy and targeted therapies will complement each other when administered concomitantly. This review will focus on the rational behind these combinations and summarise current clinical trial data.
    Review • Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • HER-2 amplification • BRAF V600 • IDH1 mutation • FGFR2 mutation • FGFR2 fusion • FGFR fusion • IDH1 mutation + BRAF V600E • NTRK fusion
    |
    cisplatin • gemcitabine • 5-fluorouracil • leucovorin calcium
    2years
    A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma (clinicaltrials.gov)
    P3, N=300, Recruiting, National Cancer Institute (NCI) | N=18 --> 300
    Enrollment change • Combination therapy
    |
    BRAF (B-raf proto-oncogene) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NF1 (Neurofibromin 1)
    |
    BRAF V600E • BRAF V600 • IDH1 mutation • IDH1 mutation + BRAF V600E
    |
    Koselugo (selumetinib) • vinblastine